| Autor: |
Felipe Moraes Toledo Pereira, Adriano Gonçalves e Silva, Aldo Lourenço Abbade Dettino, Ana Paula Garcia Cardoso, Andre Deeke Sasse, Ariel Galapo Kann, Carlos Dzik, Daniel Herchenhorn, Denis Leonardo Fontes Jardim, Diego Lopera, Mouna Ayadi, Pamela Salman, Ray Antonio Manneh Kopp, Ricardo Saraiva De Carvalho, Sandro Roberto De Araujo Cavallero, Sergio Aguiar, Vinicius Carrera Souza, Pedro Luiz Serrano Uson Junior, Andrey Soares |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
JCO Global Oncology, Vol , Iss 7, Pp 545-549 (2021) |
| Druh dokumentu: |
article |
| ISSN: |
2687-8941 |
| DOI: |
10.1200/GO.20.00507 |
| Popis: |
PURPOSETo present a summary of the recommendations for the treatment and follow-up for the biochemical recurrence of castration-resistant prostate cancer (PCa) as acquired through a questionnaire administered at the Prostate Cancer Consensus Conference for Developing Countries.METHODSA total of 27 questions were identified as relating to this topic. Responses from the clinician were tallied and are presented in percentage format. Topics included the use of imaging in staging, treatment recommendations across different patient scenarios of life expectancy and prostate-specific antigen (PSA) doubling time, and follow-up for nonmetastatic castration-resistant PCa.RESULTSA consensus agreed that in optimal conditions, positron emission tomography-computed tomography with prostate-specific membrane antigen would be used although in limited resource situations the combined use of CT of the abdomen and pelvic (or pelvic MRI), a bone scan, and a CT of the thorax or chest x-ray was recommended. In cases when PSA levels double in < 10 months, more than 90% of clinicians agreed on the use of apalutamide or enzalutamide, regardless of life expectancy. With a doubling time of more than 10 months, > 54% of experts recommended no treatment independent of life expectancy. More than half of the experts, regardless of resources, recommended follow-up with a physical examination and PSA levels every 3-6 months and imaging only in the case of symptoms.CONCLUSIONThe voting results and recommendations presented in this document can be used by physicians to support management for biochemical recurrence of castration-resistant PCa in areas of limited resources. Individual clinical decision making should be supported by available data. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
